(Q48318214)

10 February 2018

title

Hypoxia-induced decreases in SOCS3 increase STAT3 activation and upregulate VEGF gene expression (English)

1 reference

10 February 2018

0 references

Kiyotaka Yokogami

1

1 reference

10 February 2018

Shinji Yamashita

series ordinal

2

1 reference

10 February 2018

Hideo Takeshima

series ordinal

3

1 reference

10 February 2018

publication date

27 October 2012

1 reference

10 February 2018

published in

Brain Tumor Pathology

1 reference

10 February 2018

volume

30

1 reference

10 February 2018

issue

3

1 reference

10 February 2018

page(s)

135-143

1 reference

10 February 2018

https://scigraph.springernature.com/pub.10.1007/s10014-012-0122-0

exact match

0 references

cites work

Glioblastoma-derived leptin induces tube formation and growth of endothelial cells: comparison with VEGF effects

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0122-0

Anti-vascular endothelial growth factor therapy for malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0122-0

Angiogenesis in brain tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0122-0

Vascular endothelial growth factor, a potent and selective angiogenic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0122-0

Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0122-0

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0122-0

Tumorigenesis and the angiogenic switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0122-0

Biology of angiogenesis and invasion in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0122-0

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0122-0

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0122-0

A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0122-0

VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0122-0

The Stat family in cytokine signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0122-0

Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0122-0

The transcriptional network for mesenchymal transformation of brain tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0122-0

Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0122-0

Stat3 activation is required for cellular transformation by v-src

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0122-0

SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0122-0

Comparative analysis of expression of hepatocyte growth factor and its receptor, c-met, in gliomas, meningiomas and schwannomas in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0122-0

Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0122-0

Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5' enhancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0122-0

Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0122-0

CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0122-0

Suppressor of cytokine signaling-3 is a biomechanical stress-inducible gene that suppresses gp130-mediated cardiac myocyte hypertrophy and survival pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0122-0

Negative regulation of cytokine signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0122-0

Prognostic relevance of SOCS3 hypermethylation in patients with glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0122-0

Hypoxia-induced epigenetic regulation and silencing of the BRCA1 promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0122-0

Molecular mechanism of hypoxia-inducible factor 1alpha -p300 interaction. A leucine-rich interface regulated by a single cysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0122-0

Synergistic signaling in fetal brain by STAT3-Smad1 complex bridged by p300

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-012-0122-0

10.1007/S10014-012-0122-0

21 January 2018

Identifiers

DOI

1 reference

10 February 2018

1 reference

10 February 2018